We observed significant antitumor activity in a DEN-induced HCC model with MyD88 ASOs even though the ASO treatment started 6 months after DEN injection, suggesting that MyD88 might function as a major tumor promoter throughout the progression of liver cancer. Here, MYD88 is linked to liver cancer.